http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
마우스에서 BR92021(정제 브이아이 장티푸스 백신)의 감염 방어 효과
임상민(Sang Min Lim),정한선(Hahn Sun Jung),이윤경(Youn Kyeong Lee),조증근(Zeung Keun Cho),김상린(Sang Lin Kim),이영순(Yong Sun Lee) 한국독성학회 1999 Toxicological Research Vol.15 No.3
This study was performed to confirm the immunological efficacy of BR92021, vi polysaccharide typhoid vaccine, in mice. The BR92021 producing strain was less pathogenic than the challenging organism, S. typhi ty2 N4446. BR92021 completely protected the death caused by S. typhi ty2 at above 1.25 ㎍/0.5 ml/dose vaccinized by one time. At the optimally effective dose of 25 ㎍/0.5 ml of BR92021, one immunization was necessary for complete protection against S. typhi ty2-induced death. In potency test, we injected S. typhi ty2 N4446 (LD50=7.9)for the purpose of challenge to immunized mice. When injected to mice, the number of bacteria was about 1,000 CFU/0.5 ml, we observed challenged mouse for 3 days and calculated the ED50 by probits method. It was 0.037 (BR92021 ,lot No. 980001), 0.036 (BR92021, lot No. 980002), 0.032 (BR92021, lot No. 980003) and 0.045 (reference standard) ㎍/0.5 ml/mouse. This result showed that BR92021 vaccine was effective for the protection from desease caused by S. typhi ty2 infection.
기니픽을 이용한 BR92021 ( 정제 브이아이 장티푸스 백신 ) 의 항원성 평가
정태천(Tae Cheon Jeong),김갑호(Kap Ho Kim),배주현(Ju Hyun Bae),구희경(Hee Kyoung Gu),서정은(Jeong Eun Suh),박종일(Jong Il Park),차신우(Shin Woo Cha),임상민(Sang Min Lim),정한선(Hahn Sun Jung),김상린(Sang Lin Kim) 한국응용약물학회 1999 Biomolecules & Therapeutics(구 응용약물학회지) Vol.7 No.3
To study the antigenicity of BR92021(Vi polysaccharide typhoid vaccine), active systemic anaphylaxis and passive cutaneous anaphylaxis were tested in guinea pigs. The groups were as follows: group I(low dose, 30 ㎕/kg), group II(high dose, 300 ㎕/kg), group III(300 ㎕/kg plus complete Freund`s adjuvant), group IV(positive control, ovalbumin plus complete Freund`s adjuvant) and group V(saline-treated control). Male Hartley guinea pigs at 7 weeks of age were sensitized subcutaneously with the test article or saline three times per week for three weeks(i.e., total 9 times). For groups III and IV, animals were sensitized subcutaneously with either the test article or ovalbumin plus complete Freund`s adjuvant once per three week for 6 weeks(i.e., total 3 times). Twelve days after the last sensitization, the blood was collected from the sensitized animals for the passive cutaneous anaphylaxis test. In addition, the sensitized animals were subjected to the active systemic anaphylaxis test on fourteen days after the 1st sensitization by an intravenous challenge with either the test article or ovalbumin. In group I, mild(1/5) or moderate(4/5) symptoms of anaphylactic shock were observed. In group II, no sign(1/5), moderate(3/5) and severe(1/5) symptoms were observed. In group III, four animals of 5 revealed moderate signs and one of 5 showed no signs of anaphylactic shock. In group IV, all 5 animals showed severe signs of shock. In group V, one of 5 revealed moderate and four of 5 showed no signs. The necropsy findings related to the active systemic anaphylaxis were observed in most animals of groups I to V. In the passive cutaneous anaphylaxis test, the antiserum was diluted 10- to 5120- fold and was injected intradermally on the clipped back of recipient animals, followed by an intravenous challenge with either the test article or ovalbumin. No animals in groups I, II, III and V showed the positive reaction, whereas all animals in group IV, the positive control, showed the positive reaction at the dilution range of x1280 to x5120. Our results indicate that the test article, BR92021, may have weak antigenic potential in male guinea pigs.